drugset / Trial / NCT03358901
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
Phase 1
Unknown
32 enrolled
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Xiuhe Medical Technique Co.,Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
Timeline
- Start
- 2016-12
- Primary completion
- 2017-12
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YC-6 | Unknown | 100 mg | Intravenous |
| Subject | YC-6 | Unknown | 200 mg | Intravenous |
| Subject | YC-6 | Unknown | 400 mg | Intravenous |
| Subject | YC-6 | Unknown | 600 mg | Intravenous |